Results 251 to 260 of about 524,302 (394)

Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Extraintestinal manifestations (EIMs) manifest in 6%‐47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged
Giulia D'Arcangelo, Dan Turner, Oren Ledder, Esther Orlanski‐Meyer, Efrat Broide, Maya Granot, Manar Matar, Seamus Hussey, Anat Yerushalmy‐Feler, Christoph Norden, Erasmo Miele, Marina Aloi   +11 more
wiley   +1 more source

Gallstone burden and risk in Korean patients with ulcerative colitis. [PDF]

Intest Res
Jeon SR.
europepmc   +1 more source

Anti‐tumor necrosis factor‐α monotherapy versus combo therapy with immunosuppressant in pediatric inflammatory bowel disease: A real‐life study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives The aim of the study is to evaluate the efficacy of anti‐tumor necrosis factor (TNF)‐α monotherapy versus combination anti‐TNF‐α and immunosuppressive therapy. Methods A single‐center, retrospective, observational study was conducted on inflammatory bowel disease (IBD) children.
Flora Fedele, Massimo Martinelli, Caterina Strisciuglio, Elena Scarpato, Annamaria Staiano, Erasmo Miele   +5 more
wiley   +1 more source

Three Janus kinase inhibitors in ulcerative colitis: is upadacitinib taking the lead? [PDF]

Intest Res
Jung YS.
europepmc   +1 more source

Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis [PDF]

, 2015
Bindia Jharap, William J. Sandborn, Walter Reinisch, Geert D’Haens, A. M. Robinson, W. Wang, B Huang, A. Lazar, Roopal Thakkar, Jean‐Frédéric Colombel   +9 more
openalex   +1 more source

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

New England Journal of Medicine, 2013
B. Feagan, P. Rutgeerts, B. Sands, S. Hanauer, J. Colombel, W. Sandborn, G. Van Assche, J. Axler, Hyo-Jong Kim, S. Danese, I. Fox, C. Milch, S. Sankoh, T. Wyant, Jing Xu, A. Parikh   +15 more
semanticscholar   +1 more source

Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives There are no standardized criteria about stepping down from combination therapy (immunomodulator and tumor necrosis factor (TNF)‐alpha‐inhibitors) in children with inflammatory bowel disease (IBD) to reduce risk for side effects. Our aim was to describe how de‐escalation has been performed in a large pediatric cohort and to find ...
Sila Cekin, Christoph Huenseler, Serdar Cantez, Ilse Broekaert, Jan de Laffolie, CEDATA‐GPGE® Study Group   +5 more
wiley   +1 more source

Macrophages: emerging targets for ulcerative colitis. [PDF]

Front Immunol
Chen S, Qin Z, Lin X, Zhou S, Xu Y, Zhu Y.   +5 more
europepmc   +1 more source

Could the discontinuous and structurally weaker colonic mucus gel in ulcerative colitis be a result of free radical damage?

, 1998
Jo Knight, JP Pearson, MT Droy-Lefaix, Adrian Allen   +3 more
openalex   +1 more source

Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis [PDF]

, 2016
Iris Detrez, Erwin Dreesen, Thomas Van Stappen, Annick de Vries, Els Brouwers, Gert Van Assche, Séverine Vermeire, Marc Ferrante, Ann Gils   +8 more
openalex   +1 more source